[181 Pages Report] The Asthma Therapeutics Market size was estimated at USD 24.70 billion in 2023 and expected to reach USD 27.26 billion in 2024, at a CAGR 10.63% to reach USD 50.10 billion by 2030.
The asthma therapeutics market encompasses all activities related to the research, development, production, and distribution of medications and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory disorder. This market serves a diverse population of patients across age groups who require either maintenance therapy or acute care for asthmatic episodes. The market scope includes various therapeutic products such as anti-inflammatory drugs, bronchodilators, combination therapies, biologics, and delivery devices such as inhalers and nebulizers. The primary applications within the asthma therapeutics market include long-term control medicines, which aim to maintain a stable condition, and quick-relief treatments for sudden symptoms. End-users of these products typically entail individuals diagnosed with asthma, healthcare professionals like pulmonologists, and healthcare settings, including hospitals, clinics, and homecare environments. The scope extends to support services like patient education and training on the proper use of asthma management devices. The need for asthma therapeutics is increasing due to growing incidences of asthma and other respiratory diseases, recent improvements in allergy detection and diagnostic technologies, and extensive demand for monoclonal antibodies. However, the asthma therapeutics market faces certain challenges, including limitations and side effects of asthma therapeutic devices, high costs associated with advanced treatments, and limited therapeutic reach in remote and rural areas. On the other hand, several opportunities are emerging within the asthma therapeutics market, including the development of combination therapeutics for the treatment and extensive research and development (R&D) efforts for asthma treatment. There is also an increasing trend towards digital health solutions, such as smart inhalers that can track usage and remind patients about doses, opening opportunities for tech companies and pharmaceutical partnerships.
Product: Rising demand for metered dose inhalers for the treatment of asthma
Inhalers are commonly prescribed devices used by asthma patients to give medication directly to the lungs, providing immediate relief and long-term control. Dry powder inhalers (DPI) are breath-actuated devices with medicines to the lungs as a dry powder. Unlike other inhalers, DPIs do not require propellants to dispense the medication. Instead, patients must inhale quickly and deeply to ensure the powder is drawn into the lungs. DPIs are commonly prescribed for the maintenance treatment of asthma as they provide a pre-measured dose and are often considered more environmentally friendly compared to traditional metered-dose inhalers. Metered dose inhalers (MDI) are the most widely used inhalers and rely on a propellant to deliver a precise dose of medication to the lungs. Patients need to coordinate their breath with the actuation of the device. Soft mist inhaler (SMI) is a newer category of inhaler that produces a fine mist designed to enhance medication delivery to the lungs. They use mechanical force to generate a slow-moving aerosol cloud that can be easily inhaled. SMIs are less dependent on patient inhalation techniques compared to DPIs and MDIs. This feature makes them potentially more suitable for patients with difficulty with the inhalation required for DPIs or the hand-breath coordination needed for MDIs. Nebulizers are asthma therapeutic devices that convert liquid medication into a fine mist for inhalation, typically over a longer period than inhalers. They are particularly beneficial for patients who are unable to use inhalers effectively, such as young children and the elderly. Nebulizers require an external power source and are less portable than inhalers. They can be used for maintenance and rescue treatment and are often used during severe asthma exacerbations. Nebulizers are asthma therapeutic devices that convert liquid medication into a fine mist for inhalation, typically over a longer period than inhalers. They are particularly beneficial for patients who are unable to use inhalers effectively, such as young children and the elderly. Nebulizers require an external power source and are less portable than inhalers. They can be used for maintenance and rescue treatment and are often used during severe asthma exacerbations.
Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
Anti-inflammatory drugs are the cornerstone of asthma therapeutics, primarily aimed at reducing inflammation and swelling in the airways, an underlying cause of asthma symptoms. They are typically the first line of defense in asthma control. Glucocorticoids, such as fluticasone and budesonide, are widely prescribed for their capacity to reduce inflammation in the airways. These medications are available in various forms, including inhalers and pills. The inhaled form is preferred due to lower systemic side effects. Bronchodilators relax the muscles surrounding the airways, alleviating signs such as wheezing, shortness of breath, and coughing. They are divided into short-acting beta-agonists (SABAs) and long-acting beta-agonists (LABAs). SABAs, such as albuterol, are used for immediate relief during an asthma attack. They are a must-have for all asthma patients for rescue purposes. LABAs, such as salmeterol, are used for long-term control and prevention of symptoms, particularly in combination with inhaled steroids, but are not for acute episodes. Combination therapies that include anti-inflammatory agents and bronchodilators are increasingly preferred for moderate to severe asthma cases. They provide the benefit of multiple mechanisms of action in one inhaler. Common combinations such as fluticasone/salmeterol and budesonide/formoterol offer convenience and improved compliance with fewer side effects than increasing the dose of steroids alone. When comparing these drug classes, anti-inflammatories are pivotal for long-term management. Bronchodilators act fast and are crucial for acute relief but don’t address inflammation. Combination therapies provide a holistic approach but can be overprescribed for milder cases.
Route of administration: Expanding adoption of inhaled asthma medication for fast relief
Inhaled therapeutics are the cornerstone of asthma treatment. By giving medication directly to the lungs, inhaled therapeutics aim to reduce side effects and improve drug efficacy. The need for inhaled asthma medication is generally higher in patients who require fast relief from acute asthmatic episodes or for those with chronic asthma who need regular administration of medicine to keep their symptoms under control. Oral medications are an alternative to inhaled therapies and are usually prescribed for mild asthma or in cases where inhalers are not the suitable choice. The standard oral treatments include leukotriene modifiers, theophylline, and oral corticosteroids. These are generally preferred when patients have difficulty using inhalers due to coordination issues or other health problems. Oral medications tend to have a systemic effect, which may lead to an increased possibility of side effects compared to inhaled therapies.
Regional Insights
In the United States, the asthma therapeutics market is driven by a high prevalence of asthma alongside strong healthcare infrastructure. Patent expirations, novel biologics, and personalized medicine drive research and innovation in the region. Various organizations in the region continue to find a cure for and control asthma, food allergies, nasal allergies, and other allergic diseases. South America shows a growing need for asthma therapeutics, largely due to increasing awareness of respiratory diseases and improving healthcare facilities. Europe represents a substantial market for asthma therapeutics, supported by high awareness levels, established healthcare systems, and favorable reimbursement policies. The presence of several key market players and a strong emphasis on research and development activities are notable factors. Western European countries, including Germany, France, Switzerland, the United Kingdom, France, and Italy, hold a major market share, while Eastern European countries exhibit potential for growth due to improving healthcare infrastructure and rising asthma prevalence. The market in the Middle East is advancing with the development of healthcare infrastructure and increasing private sector investment. In contrast, Africa faces challenges such as limited healthcare services, low awareness, and inadequate access to treatment, which hinder market growth. However, certain countries, including South Africa, are making strides in asthma care, which can positively influence regional market development. In APAC, China’s asthma therapeutic market is developing rapidly due to the growing middle class and enhanced healthcare reforms. In Japan, patients have access to several state-of-the-art treatments, reflecting the country’s advanced healthcare system and high patient awareness. Japan’s pharmaceutical sector is highly innovative, with a robust pipeline of new drugs and consistent investment in R&D. India’s asthma treatment market is characterized by a need for affordable medications and increased education on asthma management. The high population, coupled with pollution issues, contributes to a growing prevalence of asthma. Government programs and non-profit initiatives aim to enhance asthma care accessibility and affordability throughout the subcontinent.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Asthma Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Asthma Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Koninklijke Philips N.V., Lupin Limited, Medtronic PLC, Merck & Co, Inc., Merxin Ltd., Novartis AG, Parekhplast India Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shenzhen Aeon Technology Co., Ltd., Softhale NV by invoX Pharma Limited, Sun Pharmaceutical Industries Limited, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Trudell Medical Limited, Viatris Inc., and Wellinks, Inc..
Market Segmentation & Coverage
This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Inhalers
- Dry Powder Inhalers
- Metered-Dose Inhalers
- Soft Mist Inhalers
- Nebulizers
- Inhalers
- Drug Class
- Anti-Inflammatory
- Bronchodilators
- Combination Therapy
- Route of administration
- Inhaled
- Oral
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Asthma Therapeutics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Asthma Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Asthma Therapeutics Market?
- What is the market share of the leading vendors in the Asthma Therapeutics Market?
- Which modes and strategic moves are suitable for entering the Asthma Therapeutics Market?
US $
Euro €
GBP £